Tildrakizumab for treating psoriasis.

about

Monoclonal antibodies inhibiting IL-12, -23, and -17 for the treatment of psoriasis.GATA3, HDAC6, and BCL6 Regulate FOXP3+ Treg Plasticity and Determine Treg Conversion into Either Novel Antigen-Presenting Cell-Like Treg or Th1-Treg.

P2860

Q45977850-8807B684-C005-4802-B39A-07592A40C4E8 Q49474705-88EF42A1-E75C-448F-920A-18D5147BF9FF

P2860

Tildrakizumab for treating psoriasis.

Item

http://www.wikidata.org/entity/Q39167757

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Tildrakizumab for treating psoriasis.

@en

Tildrakizumab for treating psoriasis.

@nl

type

Item

label

Tildrakizumab for treating psoriasis.

@en

Tildrakizumab for treating psoriasis.

@nl

prefLabel

Tildrakizumab for treating psoriasis.

@en

Tildrakizumab for treating psoriasis.

@nl

P1476

Tildrakizumab for treating psoriasis

@en

P2093

Luca Bianchi

http://www.w3.org/2001/XMLSchema#string

Simone D'adamio

http://www.w3.org/2001/XMLSchema#string

P2860

Effects of AIN457, a Fully Human Antibody to Interleukin-17A, on Psoriasis, Rheumatoid Arthritis, and Uveitis

Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris

A Review of Biologic Therapies Targeting IL-23 and IL-17 for Use in Moderate-to-Severe Plaque Psoriasis

Global epidemiology of psoriasis: a systematic review of incidence and prevalence

IL-23 promotes tumour incidence and growth

IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

Patient-reported outcomes for psoriasis patients with clear versus almost clear skin in the clinical setting.

IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis

P304

645-657

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/14712598.2017.1304537

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

M Galluzzo

M Talamonti

P577

2017-03-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28271735

http://www.w3.org/2001/XMLSchema#string

Tildrakizumab for treating psoriasis.

about

P2860

P2860

Tildrakizumab for treating psoriasis.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698